# Handgrip Strength and Sarcopenic Obesity

By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-08-19 | Updated: 2026-10-30

Canonical page: https://glpwatchdog.org/research/handgrip-strength-and-sarcopenic-obesity

> Over twelve months on semaglutide, handgrip strength rose 4.5 kg and sarcopenic obesity fell from 49% to 33%, while lean mass declined early then stabilized rather than continuing down.

## Key points

- Handgrip strength +4.5 kg at twelve months; sarcopenic obesity 49% → 33%.
- Lean mass fell ~3 kg by month seven and then STABILIZED instead of continuing down.
- No control group: losing 18% of fat mass could explain a stronger grip on its own.
- Prior GLP-1 use showed attenuated responses, which matters for anyone switching drugs.

Almost everything written about muscle and these drugs measures mass on a scan. The SEMALEAN study measured something better: what people could do. Over twelve months on semaglutide 2.4 mg, handgrip strength **improved by 4.5 kg**, and the prevalence of sarcopenic obesity fell from **49% to 33%**.[1]

## What happened, in order

Fat mass fell 18% by month twelve. Lean mass declined by about 3 kg by month seven, then stabilized rather than continuing down.[1]

> The lean-mass loss is front-loaded, and then it stops. It is not a slope that continues for as long as you take the drug.

That shape matters for the argument people are having. “These drugs eat your muscle” implies an ongoing process. What this describes is an early adjustment as body size falls, followed by a plateau. That is what you would expect if lean loss is a consequence of needing less muscle to move a smaller body.

## The functional results

- **Handgrip strength rose 4.5 kg** by month twelve. Grip strength is a standard, hard-to-fake proxy for whole-body strength and a well-validated predictor of outcomes.
- **Sarcopenic obesity fell from 49% to 33%**. That is a net fall in a formal diagnosis: 22% of participants lost it by month twelve and 5% newly developed it.[1]
- **Resting energy expenditure normalized to lean mass rose** between months seven and twelve, meaning the remaining tissue was not becoming metabolically sluggish.

This is consistent with a smaller study we covered in [muscle volume versus muscle function](https://glpwatchdog.org/research/muscle-volume-versus-muscle-function), where psoas volume fell 9.3% while chair-rise time and walking speed both improved slightly. Two independent studies finding mass down and function up is a more useful pattern than either alone.

> **There is no control group.** Everyone received the drug, so improvement cannot be attributed to it. People who lose 18% of their fat mass may grip harder because they are lighter and moving more, and repeated testing produces a learning effect. This is a strong signal in a design that cannot establish cause.

## Who responded differently

Three subgroup findings stand out, and one is directly practical.

1. **Women lost more weight and fat mass**, consistent with the randomized picture in [who loses more weight](https://glpwatchdog.org/research/who-loses-more-weight-on-a-glp1).
2. **People with type 2 diabetes, or prior GLP-1 use, showed attenuated responses.** The diabetes finding is well established. The prior-use one matters for anyone switching drugs (see [switching](https://glpwatchdog.org/research/switching-between-glp1-drugs)).
3. **People with a history of bariatric surgery showed the most pronounced changes**, which is relevant to the growing group taking these drugs after weight regain following surgery.

The prior-GLP-1 finding deserves particular attention because it is rarely mentioned. If you have taken one of these drugs before, the response to the next may be smaller than the trial figures suggest, because trial populations are typically drug-naive.

## Frequently asked questions

### Does semaglutide make people weaker?

This study found the opposite on a functional measure. Handgrip strength improved by 4.5 kg over twelve months and the prevalence of sarcopenic obesity fell from 49% to 33%, even though lean mass declined by about 3 kg early on.

### Does lean mass keep falling the whole time?

Not here. Lean mass declined by around 3 kg by month seven and then stabilized rather than continuing down. That is an early adjustment followed by a plateau, which is what you would expect if the loss reflects needing less muscle to move a smaller body.

### How reliable is this?

There was no control group, so improvement cannot be attributed to the drug. People who lose substantial fat may grip harder because they are lighter and more active, and repeated testing has a learning effect. It is a strong signal in a design that cannot establish cause.

### Does it work as well if you have taken a GLP-1 before?

Possibly not. People with prior GLP-1 use showed attenuated responses in this study, as did those with type 2 diabetes. Trial populations are usually drug-naive, so someone switching drugs may see less than the published figures suggest.

### What is sarcopenic obesity?

Having both excess fat and reduced muscle mass or function at the same time, a combination associated with worse outcomes than either alone. Nearly half the participants met the definition at baseline and a third after a year. That is a net change: 22% of participants lost the diagnosis and 5% newly developed it.

## References

1. Alissou M, Demangeat T, Folope V, et al. Impact of Semaglutide on fat mass, lean mass and muscle function in patients with obesity: The SEMALEAN study. Diabetes, Obesity and Metabolism. 2026. PMID: 41068996. https://pubmed.ncbi.nlm.nih.gov/41068996/

---

Cite as: GLP Watchdog, Nora Bissett, "Handgrip Strength and Sarcopenic Obesity", published 2026-08-19, updated 2026-10-30. https://glpwatchdog.org/research/handgrip-strength-and-sarcopenic-obesity

Canonical HTML page: https://glpwatchdog.org/research/handgrip-strength-and-sarcopenic-obesity

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
